DelveInsight’s “Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hyperkalemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hyperkalemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hyperkalemia: An Overview
According to the National Kidney Foundation, hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.
The risk factors for hyperkalemia include several factors such as chronic kidney disease, diabetes, congestive heart failure, and certain medications that disrupt the potassium balance. Common acute manifestations of significant hyperkalemia include muscle weakness and ECG changes, with the latter having the potential to progress to a life-threatening arrhythmia.
Hyperkalemia Market Key Facts
-
The market size in the 7MM will increase at a CAGR of 5.7% due to the increasing prevalence of the disease.
-
Among the 7MM countries, the US accounted for the highest market size of Hyperkalemia with USD 970 million in 2021 which is likely to increase by 2032.
-
Among EU4 and the United Kingdom, Germany accounted for USD 49 million in 2021, followed by the United Kingdom with USD 38 million in the same year, while Spain accounted for the lowest market with USD 4 million in 2021.
-
Japan accounted for USD 127 million in 2021, which is expected to increase by 2032.
-
In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,046 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019–2032).
-
Among the 7MM, the United States accounted for nearly 79% of the total diagnosed prevalent cases of Hyperkalemia in the 7MM in the year 2021 which is expected to increase further by 2032.
-
Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hyperkalemia pipeline therapies. It also thoroughly assesses the Hyperkalemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hyperkalemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hyperkalemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hyperkalemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hyperkalemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hyperkalemia Epidemiology, Segmented as –
-
Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019–2032]
-
Prevalent Cases of Hyperkalemia by Severity in the 7MM [2019–2032]
-
Gender-specific Prevalence of Hyperkalemia in the 7MM [2019–2032]
-
Age-Specific Diagnosed Prevalence of Hyperkalemia in the 7MM [2019– 2032]
-
Co-morbidity-specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019– 2032]
Hyperkalemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperkalemia market or expected to be launched during the study period. The analysis covers the Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hyperkalemia drugs based on their sale and market share.
The report also covers the Hyperkalemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hyperkalemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hyperkalemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/hyperkalemia-market
Hyperkalemia Companies Actively Working in the Therapeutics Market Include
-
Ardelyx
-
Zeria Pharmaceutical
-
AstraZeneca
-
Vifor Pharma
And Many Others
Emerging and Marketed Hyperkalemia Therapies Covered in the Report Include:
-
RDX013: Ardelyx
-
Sodium Zirconium Cyclosilicate (SZC)- AstraZeneca
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/hyperkalemia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hyperkalemia Competitive Intelligence Analysis
4. Hyperkalemia Market Overview at a Glance
5. Hyperkalemia Disease Background and Overview
6. Hyperkalemia Patient Journey
7. Hyperkalemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hyperkalemia Unmet Needs
10. Key Endpoints of Hyperkalemia Treatment
11. Hyperkalemia Marketed Therapies
12. Hyperkalemia Emerging Drugs and Latest Therapeutic Advances
13. Hyperkalemia Seven Major Market Analysis
14. Attribute Analysis
15. Hyperkalemia Market Outlook (In US, EU5, and Japan)
16. Hyperkalemia Companies Active in the Market
17. Hyperkalemia Access and Reimbursement Overview
18. KOL Views on the Hyperkalemia Market
19. Hyperkalemia Market Drivers
20. Hyperkalemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hyperkalemia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Platinum-Resistant Relapsed Ovarian Cancer Market
“Platinum-Resistant Relapsed Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Platinum-Resistant Relapsed Ovarian Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Platinum-Resistant Relapsed Ovarian Cancer market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology